E-drug: WHO's role in trade agreements-preferential prices
---------------------------------------------
Preferential prices are promoted by WHO and industry. At first glance
it looks like the rich subsidised the poor, but I have few questions:
1. Would it not give companies monopolies on deciding segments
and who gets what price?
2. Why do companies prefer this option to say compulsory licensing.
Is it only because they are afraid of CL products escaping to the
lucrative market in the industrialised world?
3. Would it be same price for the rich and the poor in poor countries?
4. What are the pitfalls of preferential pricing for the poor in poor
countries?
Best wishes,
Mohga Kamal Smith
Health policy Advisor
Policy Department
Oxfam, 274 Banbury Rd
Oxford OX2 7DZ, UK
Tel + 44 (0) 1865 312290
Fax +44 (0) 1865 312245
e-mail: msmith@oxfam.org.uk
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.